Astellas, Seattle Genetics bag Padcev FDA approval for advanced urothelial cancer
Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) ... Read More
Astellas Pharma to acquire US gene therapy company Audentes Therapeutics
Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about ... Read More
Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators
Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma for the research, development, and commercialization of ... Read More
Astellas Pharma acquires Potenza Therapeutics in $404.7m deal
Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued at up to $404.7 million. This strategic ... Read More
Astellas, Pfizer bag Xtandi FDA approval for non-metastatic CRPC
In a significant development, Astellas Pharma and Pfizer have announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of their cancer ... Read More